Amunix, Biogen Idec in research deal

Amunix Inc. on Wednesday announced an agreement with Biogen Idec to research and develop novel, fully-recombinant blood factors with improved therapeutic properties.
The partnership will combine Mountain View-based Amunix's protein half-life engineering expertise and Biogen Idec's research, manufacturing and clinical development of recombinant blood factors for hemophilia.

2 companies cut deal, take in cash from Index Ventures, Amunix

Versartis Inc. has completed a $21 million second round of funding, the company said Wednesday.

The round was led by New Leaf Venture Partners, which has an office in Menlo Park.

London-based Advent Venture Partners, Geneva-based Index Ventures and Mountain View-based Amunix Inc. also joined in the round.

• Versartis raises $21 million in second round

Diartis Pharmaceuticals Inc., a new company in Mountain View, got money from Index Ventures and Amunix Inc. to develop a diabetes drug it bought from Versartis Inc.
• Startup Diartis Pharmaceuticals gets money for diabetes drug development